Literature DB >> 30069579

Correlation between 5-α reductase type 2 protein expression and methylation of 5-α reductase type 2 promotor gene of benign prostatic hyperplasia.

Pil Moon Kang1, Young Jin Kim2,3, Won Tae Seo1, Su Hwan Kang1, Taek Sang Kim1, Bong Kwon Chun4, Won Ik Seo5, Jee-Yeong Jeong6,7, Jae Il Chung8.   

Abstract

PURPOSE: The enzyme 5-α reductase type 2 (5-AR 2) plays a key role in the development and maintenance of the prostate gland. We evaluated the level 5-AR 2 protein expression and the relationship between methylation of the 5-AR 2 gene-promoter and 5-AR 2 protein expression of benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS: A total of 37 prostate samples were evaluated. These included 22 samples from men undergoing transurethral prostate resections and 15 non-cancerous transition-zone human prostate tissue samples taken following radical prostatectomy. We quantified 5-AR 2 protein expression and gene-promoter methylation status using common assay procedures. Clinical variables included age, body mass index (BMI), prostate-specific antigen (PSA) levels, lipid profiles, and prostate volumes. Univariate and multivariate statistical analyses were performed followed by stepwise logistic regression modeling.
RESULTS: We were able to extract DNA from 36 of the 37 tissue samples and 10 of these (28%) did not express the 5-AR 2 protein. In total, 26 patients (72%) had methylated 5-AR 2 promoter-regions. There was a strong correlation between methylation of the 5-AR 2 promoter-regions and low-absent 5-AR 2 protein expression (p = 0.0003). Increasing age significantly predicted methylation status and protein expression level (p = 0.013).
CONCLUSIONS: The level of 5-AR 2 protein expression varies among prostate tissue samples. Methylation of the 5-AR 2 gene-promoter may account for low or absent expression of 5-AR 2 in adult human prostate tissues. Increased age correlates with increased 5-AR 2 gene-promoter methylation and decreased protein expression in men with BPH.

Entities:  

Keywords:  5-α Reductase; DNA; Hyperplasia; Methylation; Prostate

Mesh:

Substances:

Year:  2018        PMID: 30069579     DOI: 10.1007/s00345-018-2422-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  43 in total

Review 1.  DNA methylation in the immune system.

Authors:  Michael Teitell; Bruce Richardson
Journal:  Clin Immunol       Date:  2003-10       Impact factor: 3.969

Review 2.  Aging and epigenetic drift: a vicious cycle.

Authors:  Jean-Pierre Issa
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 3.  5alpha-reductase activity in the prostate.

Authors:  W D Steers
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

4.  Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.

Authors:  Yi Xu; Susan L Dalrymple; Robyn E Becker; Samuel R Denmeade; John T Isaacs
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

5.  Robust validation of methylation levels association at CPT1A locus with lipid plasma levels.

Authors:  France Gagnon; Dylan Aïssi; Alain Carrié; Pierre-Emmanuel Morange; David-Alexandre Trégouët
Journal:  J Lipid Res       Date:  2014-05-21       Impact factor: 5.922

6.  Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.

Authors:  Mark A Titus; Christopher W Gregory; O Harris Ford; Michael J Schell; Susan J Maygarden; James L Mohler
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

7.  Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study.

Authors:  S Lamon-Fava; P W Wilson; E J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-12       Impact factor: 8.311

8.  Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Authors:  G L Andriole; H A Guess; J I Epstein; H Wise; D Kadmon; E D Crawford; P Hudson; C L Jackson; N A Romas; L Patterson; T J Cook; J Waldstreicher
Journal:  Urology       Date:  1998-08       Impact factor: 2.649

Review 9.  Evolution of steroid-5alpha-reductases and comparison of their function with 5beta-reductase.

Authors:  Valérie S Langlois; Dapeng Zhang; Gerard M Cooke; Vance L Trudeau
Journal:  Gen Comp Endocrinol       Date:  2009-08-15       Impact factor: 2.822

10.  The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.

Authors:  Faris Azzouni; Alejandro Godoy; Yun Li; James Mohler
Journal:  Adv Urol       Date:  2011-12-25
View more
  3 in total

Review 1.  Epigenetic reprogramming during prostate cancer progression: A perspective from development.

Authors:  Sakshi Goel; Vipul Bhatia; Tanay Biswas; Bushra Ateeq
Journal:  Semin Cancer Biol       Date:  2021-02-02       Impact factor: 17.012

2.  METTL3 promotes prostatic hyperplasia by regulating PTEN expression in an m6A-YTHDF2-dependent manner.

Authors:  Jiaren Li; Hanyu Yao; Jin Huang; Chao Li; Yichuan Zhang; Ran Xu; Zhenting Wang; Zhi Long; Jin Tang; Long Wang
Journal:  Cell Death Dis       Date:  2022-08-19       Impact factor: 9.685

3.  Methylated CpG dinucleotides in the 5-α reductase 2 gene may explain finasteride resistance in benign prostatic enlargement patients.

Authors:  Zhe-Min Lin; Dong-Dong Fan; Song Jin; Zhan-Liang Liu; Yi-Nong Niu
Journal:  Asian J Androl       Date:  2021 May-Jun       Impact factor: 3.285

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.